Bioclinica will be exhibiting, attending and hosting numerous events in the coming months, from bio-imaging events to clinical data conferences. Please check our schedule of activities and trade shows, and come visit with us when we are in your area.

Use the Filter Events By Month below to select the specific Month and Year you would like to see.

December 8, 2016 - 1:00am (EST) to December 10, 2016 - 1:00am (EST)


Senior members of Bioclinica's Medical Imaging, Biomarkers and Research Network teams will be at the 9th Clinical Trials on Alzheimer's disease (CTAD) Congress where they'll be presenting posters and oral sessions. View list of featured presentations and arrange your one-on-one meeting here.

Event Type:

December 9, 2016 - 1:00am (EST) to December 10, 2016 - 1:00am (EST)

SCDM India

Bioclinica is proud to be the Gold Sponsor of SCDM India. Please Visit us at our booth to learn how our unmatched expertise in clinical data management can help your development programs.

Event Type:

January 23, 2017 - 1:00am (EST) to January 25, 2017 - 1:00am (EST)

Bioclinica appreciates the opportunity to sponsor DIA's Pharmacovigilance and Risk Management Strategies Conference as we are fully dedicated to the interests of Pharmacovigilance and Risk Management professionals across the globe.

Event Type:

January 24, 2017 - 1:00am (EST) to January 26, 2017 - 1:00am (EST)

SCOPE Summit

Bioclinica is pleased to sponsor the 8th Annual SCOPE Summit in Miami, Florida. Join Bioclinica on stand 404 to learn more about our leading Risk Based Monitoring (RBM) and other eHealth Solutions. Additional on-stand discussions will highlight our newest offering, Post Approval Research as well as our proven Medical imaging and Biomarker services.

Event Type:

February 1, 2017 - 1:00am (EST) to February 3, 2017 - 1:00am (EST)

3rd Annual Immuno-Oncology 360°

On Thursday, 2nd February, at 4:20 pm, Dr. J. Michael O'Neal, Chief Medical Officer, Head of Oncology, Medical Imaging, Bioclinica will present on a panel titled, "A New Approach to Modified RECIST 1.1 for Immunotherapeutics (iRECIST)." Visit Medical Imaging and Biomarker team members on the Bioclinica stand to leverage 30+ years of scientific, regulatory and operational trial expertise to advance your clinical research.

Event Type:

February 21, 2017 - 1:00am (EST) to February 23, 2017 - 1:00am (EST)

European eHealth Conference 2017

The eHealth Conference, taking place in London (February 21st - 23rd), gets you VIP access to industry leaders and forward thinkers on how to achieve better outcomes in clinical trials - all with a focus on the patient. Come share best practices and hear the latest innovations in expert panels, customer-led presentations and product demonstrations.

Event Type:

February 21, 2017 - 1:00am (EST) to February 22, 2017 - 1:00am (EST)

12th Annual Biomarkers Congress 2017

Join Bioclinica for the 12th Annual Biomarkers Congress (21-22 February 2017, Manchester UK). The Bioclinica Medical Imaging and Biomarker team invites you to visit us at our booth to discuss leveraging Bioclinica's scientific expertise and latest validated biomarkers to accelerate your clinical trial program.

Event Type:

February 22, 2017 - 1:00am (EST) to February 23, 2017 - 1:00am (EST)

Outsourcing in Clinical Trials West Coast

We invite you to visit the Bioclinica stand during OCT West. On stand discussions will include opportunities to learn more about our leading Medical Imaging, Cardiac Safety and Biomarker services and recent advancements with our eHealth solutions. The Bioclinica team is looking forward to meeting with you.

Event Type:

May 3, 2017 - 1:00am (EDT) to May 4, 2017 - 1:00am (EDT)

Bioclinica is delighted to sponsor the World Drug Safety Congress Americas, 2017. The 9th World Drug Safety Congress Americas will bring together key thought leaders and experts to explore the systems needed to empower patients, physicians, drug manufacturers and consumers to make the best drug safety decisions. The meeting is set to bridge the gap between international regulatory bodies, industry professionals and academic representatives and will address how to drive pharmacovigilance operations forward into the 21st Century.

Event Type:

On Demand Webinars by Category


Electronic Data Capture (EDC) and Data Management

CDISC Standards Briefing – Get Ready for FDA Submissions
Join Jennifer in this webinar for a detailed briefing on where we stand with CDISC implementation and what's next. Learn about recent activities surrounding CDISC standards, which support the acquisition, exchange, submission and archive of clinical research data and metadata and are accessed in 90 countries.


Clinical Trial Management Systems (CTMS)

Bridging the Gap: Managing and Maintaining CTMS and eTMF Data
In this webinar, clinical trial experts Dirk Beth of arivis, a Bioclinica App xChange Partner, and Bioclinica's Jeremiah Rehm will explore the possibilities of single source data across CTMS/eTMF systems. This approach can bring increased efficiencies in a number of important areas, such as elimination of redundant work processes and reconciliation of CTMS/eTMF data.

Back to Top


Randomization and Trial Supply Management (RTSM)

What Value Does Forecasting and Demand Planning Technology Bring to the Management of the End-to-end Clinical Supply Chain?
Forecasting and demand planning tools provide insight to what is truly happening in a clinical trial. They give the transparency required to make timely and educated decisions with regards to clinical trial supply plans and connect people and processes to streamline the forecasting, planning and optimization of the supply chain.


Risk-Based Monitoring

What Effect Does ICH E6 R2 Have on Risk-Based Monitoring and Overall Quality Risk Management?
With the aim of improving efficiencies in trial conduct while ensuring participant safety, regulatory guidelines have recently undergone revision. The revision to the ICH Guideline for Good Clinical Practice (E6 R2) primarily addresses quality management with a focus on risk identification, evaluation, control, review and reporting. With the pending adoption of these revised guidelines, it's time to evaluate how your organizational structure and processes will be affected.

Back to Top


Post-Approval Research

Patient Centric Post-Approval Research: It's Time to Rethink How Post-Approval Studies Are Done
With an evolving role and complexities of post-approval studies – and a shift toward patient centric outcomes – it is imperative that we revisit the way post-approval research is conducted.

Conducting Post-Approval Research Requires a Unique Mindset and Specialized Infrastructure. Do You Have What it Takes?
There are fundamental differences in conducting research in pre-market randomized controlled trials (RCT) versus post-approval. These differences are not only in the study intent and objectives but the operations and conduct.


Safety and Relgulatory Solutions

Cloud-Based Tool Aims to Improve Global Drug Safety & Regulatory Efficiencies While Remaining Compliant
Keeping up with the increasing and evolving safety and pharmacovigilance obligations around the globe can be a major challenge.

In this webinar, she will discuss upcoming changes in global drug safety regulatory requirements and will demonstrate how Bioclinica's drug safety regulatory intelligence tool, RITrace, can improve efficiencies and help you remain compliant.

Marketing Medicines in the EU - Pharmacovigilance Requirements
In this complimentary webinar the Chief Safety Advisor for Synowledge (a Bioclinica company) provides expert insight into good pharmacovigilance practices (GVP) modules within EU legislation. Any pharmaceutical company wishing to market products within the EU must be aware of their legal requirements under the legislation. This webinar is suitable for all staff working in the safety and regulatory area. It is an opportunity to gain an understanding of the legislation at a high level and ask specific questions relating to your business.

Finding the Right End-to-End Safety Solution for Your Needs
With upcoming changes, including the implementation of E2B(R3) and IDMP standards, the current state of safety reporting in clinical trials can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets in the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.


Financial Lifecycle Solutions

Clinical Trial Forecasting: Managing the Challenges and Avoiding the Fines
With globalization, large numbers of sites, recent regulatory requirements and an increasing number of CROs and vendors, clinical trials are constantly becoming more complex. Given that clinical trial costs are one of the biggest expense categories for biopharmaceutical companies—the average cost of bringing a drug to market in the US is estimated to be $1.3-1.7 billion—it's critical that CROs and Sponsors forecast accurately.

However, manual processes have made forecasting of clinical trials challenging, leading to difficulties in reforecasting and cash management (and as a result, difficulties in maintaining site satisfaction) as well as hefty fines.


Medical Imaging

Critical Regulatory Considerations for Imaging Trials: What You Need to Know
Medical Imaging plays a significant role in the conduct of clinical trials and bringing new therapies to market. However, as application of medical imaging in clinical studies grow, so does the complexity of regulations on a trial's conduct. The more sites, patients and modalities in a trial, the more complex the regulatory and workflow compliance.

Back to Top


Cardiac Safety

Recent Advances and Critical Review of The Intensive QT Study As a Replacement to The TQT Study: Are We There Yet?
In July 2013 the US FDA presented an initiative to replace the ICH-E14 mandated Thorough QT (TQT) study with a set of non-clinical assays, collectively termed 'Comprehensive In Vitro Pro-arrhythmia Assay' (CiPA). The non-clinical CiPA paradigm is complemented by an Early Phase cardiac safety assessment, involving routine Phase 1 single and multiple ascending dose (SAD/MAD) studies with intensive ECG (QT) and PK sampling, designated the Intensive QT (IQT) study.

Back to Top